# Insulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes

Study · id `cardio:ct-nct07747402` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07747402](<https://clinicaltrials.gov/study/NCT07747402>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07747402

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 462 participants.

## Technical summary

Registry record NCT07747402. Randomized; no masking; primary purpose treatment. Start 2027-01 (anticipated); primary completion 2027-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 462 participants (planned count; ClinicalTrials.gov record NCT07747402, source copy `cardio:ctgov-nct07747402-2026-08-05`, retrieved 2026-10-26)
- Planned start: 2027-01 (anticipated) (ClinicalTrials.gov record NCT07747402, source copy `cardio:ctgov-nct07747402-2026-08-05`, retrieved 2026-10-26)
- Primary completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT07747402, source copy `cardio:ctgov-nct07747402-2026-08-05`, retrieved 2026-10-26)
- Completion: 2028-03 (anticipated) (ClinicalTrials.gov record NCT07747402, source copy `cardio:ctgov-nct07747402-2026-08-05`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07747402, source copy `cardio:ctgov-nct07747402-2026-08-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07747402-2026-08-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Insulin Icodec Initiation Strategies and Day-4 Supplemental Dosing in Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Insulin icodec
- Lead sponsor: Xi'an International Medical Center Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 372d8bc36b1449f9b1689d3fd125ae041b1634d32d710b6c059ffed93647bd51
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
